Laboratory of Cellular and Molecular Immunology, Centro de Pesquisas René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil.
Vaccine. 2013 Apr 3;31(14):1785-92. doi: 10.1016/j.vaccine.2013.01.048. Epub 2013 Feb 8.
Zoonotic visceral leishmaniasis, caused by the intracellular protozoan parasite Leishmania infantum, is a neglected tropical disease that is often fatal when untreated. Dogs are considered the main reservoir of L. infantum in zoonotic VL as the presence of infected dogs may increase the risk for human infection. Canine visceral leishmaniasis (CVL) is a major veterinary and public health problem in Southern Europe, Middle East and South America. Control of animal reservoirs relies on elimination of seropositive dogs in endemic areas. However, treatment of infected dogs is not considered a favorable approach as this can lead to emergence of drug resistance since the same drugs are used to treat human infections. Therefore, vaccination against CVL remains the best alternative in control of the animal reservoirs. In this study, we present data on the immunogenicity profile of a live attenuated parasite LdCen(-/-) in a canine infection model and compared it to that of Leishmune(®), a commercially available recombinant vaccine. The immunogenicity of the LdCen(-/-) parasites was evaluated by antibody secretion, production of intracytoplasmic and secreted cytokines, activation and proliferation of T cells. Vaccination with LdCen(-/-) resulted in high immunogenicity as revealed by the higher IgGTotal, IgG1, and IgG2 production and higher lymphoproliferative response. Further, LdCen(-/-) vaccinated dogs showed higher frequencies of activated CD4+ and CD8+ T cells, IFN-γ production by CD8+ T cells, increased secretion of TNF-α and IL-12/IL-23p40 and decreased secretion of IL-4. These results contribute to the understanding of immunogenicity elicited by live attenuated L. donovani parasites and, consequently, to the development of effective vaccines against visceral leishmaniasis.
人兽共患内脏利什曼病由细胞内原虫寄生虫利什曼原虫引起,是一种被忽视的热带病,未经治疗通常是致命的。狗被认为是人兽共患内脏利什曼病的主要传染源,因为感染狗的存在可能会增加人类感染的风险。犬内脏利什曼病(CVL)是欧洲南部、中东和南美洲主要的兽医和公共卫生问题。控制动物病源依赖于消除流行地区的血清阳性犬。然而,治疗感染犬并不被认为是一种有利的方法,因为这可能导致药物耐药性的出现,因为相同的药物用于治疗人类感染。因此,针对 CVL 的疫苗接种仍然是控制动物病源的最佳选择。在这项研究中,我们提供了在犬感染模型中减毒寄生虫 LdCen(-/-)的免疫原性概况的数据,并将其与商业化的重组疫苗 Leishmune(®)进行了比较。通过抗体分泌、细胞内和分泌细胞因子的产生、T 细胞的激活和增殖来评估 LdCen(-/-)寄生虫的免疫原性。LdCen(-/-)疫苗接种导致高免疫原性,表现为 IgGTotal、IgG1 和 IgG2 产生更高,淋巴细胞增殖反应更高。此外,LdCen(-/-)疫苗接种犬显示出更高频率的激活 CD4+和 CD8+T 细胞、CD8+T 细胞产生 IFN-γ、TNF-α 和 IL-12/IL-23p40 分泌增加以及 IL-4 分泌减少。这些结果有助于理解活的减毒利什曼原虫寄生虫引起的免疫原性,从而开发针对内脏利什曼病的有效疫苗。